LOS ANGELES, March 08, 2025 (GLOBE NEWSWIRE) — ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to an integrase inhibitor-based antiretroviral regimen increased the risk of weight gain and cardiometabolic complications over the next five years compared to remaining on a regimen without an […]
An ACTG study presented at CROI 2025 found that switching to an integrase inhibitor-based HIV regimen increased the risk of obesity, diabetes, hypertension, and metabolic syndrome, but not major adverse cardiovascular events, over five years. The study analyzed data from the REPRIEVE trial involving over 2,700 participants. While the increased risk was small, the study suggests close monitoring for cardiometabolic complications in individuals on integrase inhibitors.
